AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03554330 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiofrequency catheter ablation
Description: (1) In control group: only graded balloon atrial septostomy will be carried out and there is no radiofrequency catheter ablation. (2) In single-RFA group: after graded balloon atrial septostomy identical to control group, radiofrequency catheter ablation will be performed immediately around the rim of created inter-atrial fenestration. (3) In double-RFA group: the first step is radiofrequency catheter ablation on fossae ovalis; and then the other two steps are identical to the single-RFA group (BAS and RFA around the rim of fenestration).
Study NCT03554330 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Balloon atrial septostomy
Description: Graded balloon atrial septostomy is performed in all patients.
Study NCT02339363 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sitting Meditation
Description: 4 weeks Sitting Meditation
Study NCT03929484 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal reservoir cannula
Description: The experimental oxygen mask (nasal reservoir cannula) fits over a standard nasal cannula. The system is designed to reduce administered oxygen to deliver an equal or higher fraction of inspired oxygen (FiO2) per oxygen delivered (L/min) compared with a standard nasal cannula alone.
Study NCT02339363 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hatha yoga
Description: 4 weeks of Hatha yoga
Study NCT01487499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 40 mg in 40 mL of normal saline for each of 4 bronchoscopies
Study NCT02798406 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNX-2401
Description: On Day 0, following brain tumor biopsy and confirmation of recurrent tumor, a single injection of DNX-2401 is administered directly into the brain tumor.
Study NCT02798406 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Sequential intravenous administration every three weeks beginning 7-9 days after Day 0/DNX-2401
Study NCT03554330 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balloon atrial septostomy
Description: Graded balloon atrial septostomy is performed in all patients.
Study NCT04194697 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise program
Study NCT04194697 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: No exercise
Description: No exercise program
Study NCT01175837 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies: Pre- and post-fasting side effect questionnaires
Study NCT01175837 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: preventative dietary intervention
Description: 24, 36, or 48 hour fast prior to chemotherapy
Study NCT01175837 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT04082832 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cu(II)ATSM
Description: oral suspension
Study NCT04082832 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: oral suspension
Study NCT00443612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan/Hydrochlorothiazide
Description: Administration of irbesartan 150 mg/day + hydrochlorothiazide 12.5 mg
Study NCT00443612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan
Description: Administration of irbesartan 150 mg/day
Study NCT04867239 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: A two-day education progra
Description: During the camp, the multidisciplinary team provided disease information, lifestyle modification, nutrition, and exercise.
Study NCT04012918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine plus aromatase inhibitor
Description: Capecitabine 625 mg/m2 bid PO for 14 days to be repeated every 21 days until progression in combination with aromatase inhibitor if postmenopausal, addition of LHRH agonist will be added if premenopausal.
Study NCT04012918 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A.I.
Description: aromatase inhibitors ( letrozole 2.5 mg PO per day or Anastrozole 1 mg PO per day or aromasin 25 mg PO per day) if post-menopausal, if premenopausal leutnising hormone releasing hormone (LHRH) agonist will be added to the aromatase inhibitor
Study NCT02878824 — intervention group
Intervention type: OTHER
Intervention: Ethnicity
Description: As mentioned by Goldberger and Veroff (1995) the concept of ethnicity is also associated with culture and is often used interchangeably with culture as well as with race. Ethnic differences are not necessarily inherited, but they are learned through constant exposure; however have strong genetic influences that explain consequent behavioural differences between different ethnic groups (Chudek \& Henrich, 2011). An individual's genetic makeup greatly affects their behaviours (Klahr \& Burt, 2014).~In this study, we look at exposure to different ethnicity as exemplified by comparison between two groups of typically-developing children from different ethnicity (Chinese children in Hong Kong and Filipino Children in Hong Kong).
Study NCT01658358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: * dose level I, II 1000mg po daily~* dose level III, IV 1250mg po daily
Study NCT01658358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipo-Dox
Description: at the dose level reached on days 1 of a 21 days cycle. The recommended duration of combination treatment for each patient is at least 8 cycles,
Study NCT02878824 — intervention group
Intervention type: OTHER
Intervention: Environment
Description: The living environment has been implicated to have an effect on a person's psychological functioning (Rutter, Picker, Murray \& Eaves, 2001) and eventually how behaviour is manifested. The proposed disparity or effects between urban and rural dwelling is built on research that looks at the restorative and calming features of the natural environment, as well as the chaotic organization of the living spaces in urban settings.
Study NCT04258189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64417184
Description: Single dose of JNJ-64417184 solution (with or without preservatives) will be administered orally.
Study NCT02753465 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: left colic artery
Description: Laparoscopic D3 Lymph Node Dissection with preservation of left colic artery
Study NCT02753465 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High ligation
Description: Laparoscopic D3 Lymph Node Dissection with ligation above the left colic artery
Study NCT03200535 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EHR gaps
Description: Gaps will appear in the electronic health record and patient portal in order to prompt referral by provider or patient
Study NCT03200535 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bulk outreach
Description: A bulk letter or email will be sent
Study NCT03213457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol/Norethindrone Acetate
Description: Tablets
Study NCT03213457 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Elagolix
Description: Tablet
Study NCT03213457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix
Description: Tablet
Study NCT03213457 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for E2/NETA
Description: Tablets
Study NCT00295828 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pegaptanib Sodium Injection/Panretinal Photocoagulation
Description: Pegaptanib Sodium Injection is a single dose prefilled syringe and is formulated as a 3.47 mg/mL solution. Combined with an ocular laser procedure.
Study NCT00295828 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Panretinal Photocoagulation (PRP)
Description: Ocular Laser Procedure
Study NCT03162731 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT03162731 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study NCT03162731 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Simultaneous-Integrated Boost Intensity-Modulated Radiation Therapy
Description: Undergo simultaneous integrated boost integrated modulated radiation therapy
Study NCT04727775 — intervention group
Intervention type: DRUG
Intervention: Remdesivir
Description: Antiviral drugs
Study NCT03200535 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietician call
Description: Patients will receive a personalized call by a registered dietitian
Study NCT02115854 — intervention group
Intervention type: OTHER
Intervention: labial biopsy
Study NCT03647319 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-frequency rTMS on left DLPFC+anodal tDCS on right DLPFC
Description: 10Hz rTMS over the left DLPFC and anodal tDCS over the right DLPFC are simultaneously stimulated.
Study NCT03162731 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Volume Modulated Arc Therapy
Description: Undergo volumetric modulated arc therapy
Study NCT02343133 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HemaMax
Study NCT02343133 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03722199 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: flavanols (subgroup of polyphenols, subgroup of phenolics, natural substances)
Description: single intake of capsules with flavanols (subgroup of polyphenols, subgroup of phenolics, natural substances)
Study NCT03722199 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: single intake of capsules with a placebo
Study NCT02587039 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic pre-conditioning
Description: Remote ischemic preconditioning is exposure to a brief period ischemia to an area or limb that is not involved in surgery. This intervention is believed to reduce the incidence of cerebral (brain) ischemia during cardiac surgery.
Study NCT02587039 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Delirium Assessment
Description: The Delirium assessment consist of a validated psychiatric screening tool called the Confusion Assessment Method. We will use this tool to determine if patients have any confusion after surgery.
Study NCT02587039 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delirium Assessment
Description: The Delirium assessment consist of a validated psychiatric screening tool called the Confusion Assessment Method. We will use this tool to determine if patients have any confusion after surgery.
Study NCT02834377 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment algorithm targeting individual cardiac output
Study NCT02588937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EntecaBell ODT. 0.5mg
Study NCT02588937 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baraclude Tab. 0.5mg
Study NCT00729599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetylpyridinium chloride
Description: Cetylpyridinium chloride during 21 consecutive days.
Study NCT03213600 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial Direct Current Stimulation tDCS
Description: 75 participants will receive 20 minutes of active tDCS (1,5mA, 20 minutes stimulation over frontal (F3/F4) electrodes ); A group of 75 participants will receive 1,5mA 20 minutes of stimulation over parietal (CP3 CP4) electrodes. During this stimulation session and we will also measure your ability to perceive visual and auditory objects presented by a computer, while recording your brain activity using electroencephalography or EEG (a technique using electrodes that measures the electrical activity of your brain)
Study NCT02412436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depot medroxyprogesterone acetate
Description: Depot medroxyprogesterone acetate intramuscular injection
Study NCT03659721 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FACAM
Description: Support person
Study NCT03659721 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Care as Usual
Description: Usual care
Study NCT03659721 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COS-P
Description: Attachment based therapy
Study NCT03186183 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GPS program
Description: GPS is a sexual health promotion and HIV prevention program. It has 4 components: provision of information on HIV and sexually transmitted infections, motivational interviewing counselling, sexual health behavioural skills building, and linkage to care in the local community (e.g., referrals to medical, social service, social, mental health, and substance use programs). Among HIV-positive men who have sex with men (MSM) GPS is associated with positive health outcomes including decreased likelihood of condomless anal sex (CAS), particularly CAS with serodiscordant partners. GPS is also associated with decreased fear of being rejected for insisting on condom use and increased condom use self-efficacy.
Study NCT00392288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclesonide
Description: Ciclesonide MDI 40 µg BID over twelve weeks
Study NCT00392288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclesonide
Description: Ciclesonide MDI 80 µg BID over twelve weeks
Study NCT00392288 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo MDI over twelve weeks
Study NCT02544763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GWP42003-P
Description: Yellow oily solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
Study NCT02544763 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Yellow oily solution containing the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
Study NCT04145245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocarnitine
Description: Levocarnitine syrup- oral supplementation about 1500 mg/day for 10 weeks
Study NCT03647319 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-frequency rTMS on left DLPFC+cathodal tDCS on right DLPFC
Description: 10Hz rTMS over the left DLPFC and cathodal tDCS over the right DLPFC are simultaneously stimulated.
Study NCT02370147 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking reduction intervention
Description: Smokers was informed that many harmful effects were proved to be related with smoking, such as cancer, coronary heart disease, respiratory disease and many other health problems, and one out of two smokers will be killed by smoking. Smokers will be advised to reduce smoking consumption for at least half of their total consumption in the next month. Finally, all smokers were warned to keep in mind that the current attempt to reduce smoking is an intermediate step before the complete cessation.
Study NCT03213600 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial Direct Current Stimulation tDCS
Description: 75 participants will receive 20 minutes of active tDCS (1,5mA, 20 minutes stimulation over frontal (F3/F4) electrodes ); A group of 75 participants will receive 1,5mA 20 minutes of stimulation over parietal (CP3 CP4) electrodes. During this stimulation session and we will also measure your ability to perceive visual and auditory objects presented by a computer, while recording your brain activity using electroencephalography or EEG (a technique using electrodes that measures the electrical activity of your brain)
Study NCT02370147 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise and diet advice control
Description: Smokers will be asked to do regular activities for three or four times per week, and to have a healthy and balanced diet, having more fruit and vegetables which are rich in vitamins, high in nutrition yet low in calories. In the whole process, advises will not refer to smoking cessation or smoking reduction.
Study NCT03019263 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutraceutical
Description: Nutritional counseling plus one pill of an active product (Trixy®) containing Berberine, Tocotrienols and Chlorogenic acid
Study NCT03079180 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength training at 80% 1RM
Description: Detailed in Arms section's
Study NCT03079180 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength training at 55% 1RM
Description: Detailed in Arms section's
Study NCT01046370 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Amygdala Retraining Program
Description: Mind-body intervention.
Study NCT01413477 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcipotriol, Betamethasone, Calcipotriol & Betamethasone
Description: All study patients will be randomized to receive one of four topical ointments (calcipotriol, betamethasone dipropionate, combination of both calcipotriol/betamethasone dipropionate, or Vaseline petroleum jelly). Each subject will receive one unlabelled 5g tube for application to be dispensed by pharmacist, Rudy Chin. We expect approximately 2g of TOTAL use (0.125g applied twice daily over a 5 cm x 5 cm area on one forearm for 7 days). Typically, topical steroids such as betamethasone dipropionate have been used for treating a number of inflammatory skin conditions, including eczema. In addition, vitamin D analogues such as calcipotriol are used to treat psoriasis. Both agents, in our study, will be used on a small area of normal skin for a short 7 day course.
Study NCT01413477 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Calcipotriol, Betamethasone, Calcipotriol & Betamethasone
Description: All study patients will be randomized to receive one of four topical ointments (calcipotriol, betamethasone dipropionate, combination of both calcipotriol/betamethasone dipropionate, or Vaseline petroleum jelly). Each subject will receive one unlabelled 5g tube for application to be dispensed by pharmacist, Rudy Chin. We expect approximately 2g of TOTAL use (0.125g applied twice daily over a 5 cm x 5 cm area on one forearm for 7 days). Typically, topical steroids such as betamethasone dipropionate have been used for treating a number of inflammatory skin conditions, including eczema. In addition, vitamin D analogues such as calcipotriol are used to treat psoriasis. Both agents, in our study, will be used on a small area of normal skin for a short 7 day course.
Study NCT04145245 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levocarnitine
Description: Levocarnitine syrup- oral supplementation about 1500 mg/day for 10 weeks
Study NCT02703623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Given PO
Study NCT02703623 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone Acetate
Description: Given PO
Study NCT02703623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Given PO
Study NCT02703623 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apalutamide
Description: Given PO
Study NCT02703623 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabazitaxel
Description: Given IV
Study NCT02703623 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV
Study NCT02703623 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study NCT02703623 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02079363 — intervention group
Intervention type: OTHER
Intervention: No interventions, this is an observational study
Study NCT01802216 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and root planing
Description: non-surgical periodontal disease treatment
Study NCT03647319 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-frequency rTMS on left DLPFC+sham tDCS on right DLPFC
Description: 10Hz rTMS over the left DLPFC and sham tDCS (no stimulation) over the right DLPFC are simultaneously stimulated.
Study NCT02703623 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01802216 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minocycline
Description: antibiotic microspheres
Study NCT02703623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO
Study NCT02703623 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Given PO
Study NCT03868124 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: G2-TR intraocular implant containing travoprost
Description: Provided in Arm/Group descriptions
Study NCT03868124 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sham surgery + active-comparator eye drops
Description: Sham surgery plus postoperative active-comparator eye drops (Timolol Maleate ophthalmic solution, 0.5%)
Study NCT02449616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MST-188
Description: Intravenous administration as 100 mg/kg for 1 hour followed by 30 mg/kg/hour for up to 48 hours.